Could This FDA Milestone Unlock Gilead’s (GILD) Next Big Growth Driver?

On June 15, Gilead Sciences, Inc. (NASDAQ:GILD) announced that the U.S. Food and Drug Administration accepted its supplemental New Drug Application for Yeztugo 300-mg tablets arsenic a imaginable once-weekly oral pre-exposure prophylaxis (PrEP) attraction for HIV prevention. The Food and Drug Administration assigned a Prescription Drug User Fee Act (PDUFA) people enactment day of February 2, 2027, marking an important regulatory milestone for the program. If approved, the therapy could grow Gilead's HIV prevention portfolio by offering patients a convenient once-weekly oral dosing option.

On June 12, Gilead Sciences, Inc. (NASDAQ:GILD) announced the donation of much than 2,000 vials of its intravenous antiviral therapy remdesivir to the Republic of Uganda to enactment efforts to combat the ongoing Ebola Bundibugyo microorganism outbreak. The company stated that the donation reflects its committedness to responding rapidly to planetary wellness emergencies and leveraging its extended acquisition successful infectious illness management. Management emphasized that Gilead is moving intimately with partners and wellness authorities to assistance code the outbreak and enactment affected communities.

Founded successful 1987 and headquartered successful Foster City, California, Gilead Sciences, Inc. (NASDAQ:GILD) is simply a biopharmaceutical institution that discovers, develops, and commercializes innovative therapeutics for life-threatening diseases, peculiarly successful virology, oncology, and inflammation. It transforms fatal & chronic conditions (like HIV and Hepatitis C) into highly manageable, semipermanent states of health.

While we admit the imaginable of GILD arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Most Overvalued Quantum Computing Stocks According to Short Sellers and 7 Best Pet Care Stocks to Buy for Consistent Recurring Revenue.

Disclosure: None.  Follow Insider Monkey connected Google News.